Get the Stockscreener App
91.02
2.15%
-2.00
After Hours:
91.02
Nuvalent Inc stock is traded at $91.02, with a volume of 474.53K.
It is down -2.15% in the last 24 hours and up +8.07% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$93.02
Open:
$91.67
24h Volume:
474.53K
Relative Volume:
0.99
Market Cap:
$6.07B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-23.34
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-10.08%
1M Performance:
+8.07%
6M Performance:
+17.51%
1Y Performance:
+1.66%
1-Day Range:
$90.50
$93.61
1-Week Range:
$90.50
$104.90
52-Week Range:
$55.53
$104.90
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
91.02 | 6.76B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent to present zidesamtinib patient data at lung cancer conference - Investing.com
Nuvalent unveils patient outcomes data at key cancer conference - Traders Union
Nuvalent (NASDAQ: NUVL) to present ARROS-1 PRO and pivotal efficacy/safety at IASLC ASCO - Stock Titan
Published on: 2025-11-04 11:51:01 - newser.com
Will Nuvalent Inc. bounce back from current support2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
Can Nuvalent Inc. stock maintain growth trajectoryMarket Performance Report & Free Real-Time Volume Trigger Notifications - newser.com
How Nuvalent Inc. stock trades during market volatilityMarket Growth Review & Free Reliable Trade Execution Plans - newser.com
Will Nuvalent Inc. stock rally after Fed decisionsQuarterly Portfolio Summary & Community Consensus Trade Signals - newser.com
Can volume confirm reversal in Nuvalent Inc.2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
How risky is Nuvalent Inc. stock now2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull market2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Why Nuvalent Inc. stock remains resilientJuly 2025 Market Mood & Target Return Focused Picks - newser.com
What momentum indicators show for Nuvalent Inc. stockTrade Ideas & Long Hold Capital Preservation Tips - newser.com
Why analysts remain bullish on Nuvalent Inc. stockMarket Weekly Review & Momentum Based Trading Ideas - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthWall Street Watch & Technical Entry and Exit Alerts - newser.com
Published on: 2025-11-02 23:09:14 - newser.com
What data driven models say about Nuvalent Inc.’s futureTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - newser.com
Using economic indicators to assess Nuvalent Inc. potentialBond Market & Real-Time Stock Price Movement Reports - newser.com
Custom strategy builders for tracking Nuvalent Inc.2025 Market Overview & Real-Time Volume Analysis - newser.com
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - MSN
Barclays Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Nuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 21,800 Shares - MarketBeat
Applying sector rotation models to Nuvalent Inc.Weekly Trading Summary & Pattern Based Trade Signal System - newser.com
Piper Sandler Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Centene (CNC) and Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc Reports Q3 2025 EPS of -$1.70, Missing Estimates; S - GuruFocus
What moving averages say about Nuvalent Inc.July 2025 Update & Breakout Confirmation Trade Signals - newser.com
Nuvalent price target raised to $132 from $114 at UBS - MSN
Nuvalent price target raised to $120 from $105 at Goldman Sachs - TipRanks
Nuvalent (NASDAQ:NUVL) Announces Earnings Results - MarketBeat
Barclays Raises Price Target for Nuvalent (NUVL) to $112.00 | NU - GuruFocus
Nuvalent Executives Sell Shares Under Trading Plans - TradingView
NUVL insider trades: 4,000 options exercised, 4,000 shares sold - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
UBS Adjusts Price Target on Nuvalent to $132 From $114, Maintains Buy Rating - MarketScreener
Nuvalent stock price target raised to $132 by UBS on cancer drug progress - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):